Event-free survival after 68 Ga-PSMA-11 PET/CT in recurrent hormone-sensitive prostate cancer (HSPC) patients eligible for salvage therapy
Francesco Ceci(University of Turin), Désirèe Deandreis, Paolo Gontero(Fondazione Ricerca Molinette), Giuseppe Carlo Iorio(Azienda Ospedaliera Citta' della Salute e della Scienza di Torino), Umberto Ricardi(University of Turin), Guido Rovera(Università Cattolica del Sacro Cuore), Marco Oderda(University of Turin), Séréna Grimaldi(Université Paris-Saclay), Roberto Passera(Azienda Ospedaliera Citta' della Salute e della Scienza di Torino), Sara Dall’Armellina(University of Turin), Marilena Bellò, Valeria Chiofalo(Azienda Ospedaliera Citta' della Salute e della Scienza di Torino), Alessia Guarneri(Azienda Ospedaliera Citta' della Salute e della Scienza di Torino), Virginia Liberini(University of Turin)
European Journal of Nuclear Medicine and Molecular Imaging
February 26, 2022
Cited by 26
Related Papers
Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group
|Journal of Clinical Oncology|2015|2.2k
Characterisation and classification of oligometastatic disease: a European Society for Radiotherapy and Oncology and European Organisation for Research and Treatment of Cancer consensus recommendation
|The Lancet Oncology|2020|1.1k
Selumetinib-Enhanced Radioiodine Uptake in Advanced Thyroid Cancer
|New England Journal of Medicine|2013|825
Defining oligometastatic disease from a radiation oncology perspective: An ESTRO-ASTRO consensus document
|Radiotherapy and Oncology|2020|646